Similar articles

• Oral anticoagulation is not necessary for patients with bioprosthetic mitral valve replacement in atrial fibrillation.

  Nuñez L, Pinto AG, Larrea JL, Gil Aguado M, Connor FO. Nuñez L, et al. Z Kardiol. 1986;75 Suppl 2:321-5. Z Kardiol. 1986. PMID: 3727711 No abstract available.
• Low profile bioprostheses for mitral valve replacement.

  Romano M, Sigal R, Lorente P, Piwnica A. Romano M, et al. Z Kardiol. 1986;75 Suppl 2:305-7. Z Kardiol. 1986. PMID: 3727708 No abstract available.
• Factors influencing thromboembolism after mitral prosthetic implants.

  Rábago G, Fraile J, Martinell J, Artiz V, Cortina J. Rábago G, et al. Z Kardiol. 1986;75 Suppl 2:341-4. Z Kardiol. 1986. PMID: 2425504 No abstract available.
• Mitral valve disease: if the mitral valve is not reparable/failed repair, is bioprosthesis suitable for replacement?

  Jamieson WR, Gudas VM, Burr LH, Janusz MT, Fradet GJ, Ling H, Germann E, Lichtenstein SV. Jamieson WR, et al. Eur J Cardiothorac Surg. 2009 Jan;35(1):104-10. doi: 10.1016/j.ejcts.2008.08.021. Epub 2008 Dec 3. Eur J Cardiothorac Surg. 2009. PMID: 19056294 Review.
• Mitral valve replacement and thromboembolic risk.

  Benussi S, Verzini A, Alfieri O. Benussi S, et al. J Heart Valve Dis. 2004 May;13 Suppl 1:S81-3. J Heart Valve Dis. 2004. PMID: 15225011 Review. No abstract available.